Phase I/II trial of weekly nab-Paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations (OLCSG1303)

Shinobu Hosokawa, Akihiro Bessho, Daijiro Harada, Toshiyuki Kouzuki, Katsuyuki Hotta, Naoyuki Sone, Shoichi Kuyama, Shingo Harita, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)ix83
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
DOIs
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this